Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 26;4(1):vdac080. doi: 10.1093/noajnl/vdac080

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 8. — Pseudoresponse following bevacizumab therapy in a 15 year old male patient with recurrent high grade glioma with histone H3.3 G34 mutation in the left temporal lobe. Extensive heterogenous enhancement (A, post-contrast T1-weighted image) and edema with mass effects (D, FLAIR image) have been significantly reduced 3 weeks after the start of bevacizumab therapy (B, E, post-contrast T1-weighted image and FLAIR image, respectively); however, there is evidence of worsening of enhancement (C, motion degraded post-contrast T1-weighted image) and infiltrative tumor component (F, FLAIR image), on a follow-up MRI obtained 8 weeks after the start of bevacizumab therapy.